Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 103.09m |
Free float | 63.74m |
P/E (TTM) | -- |
Market cap | 97.92m USD |
EPS (TTM) | -0.1726 USD |
--
More ▼
Announcements
- Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
- Tiziana Life Sciences Appoints New Chief Executive Officer
- Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
- Tiziana Life Sciences Granted FDA Fast Track Designation
- Tiziana Receives $3.4 Million in Non-Dilutive Funding
- Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
- FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
- Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
- Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
- Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
More ▼